On Tuesday, Prime Medicine Inc (NASDAQ: PRME) was 0.57% up from the session before settling in for the closing price of $1.75. A 52-week range for PRME has been $1.71 – $8.27.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
A company in the Healthcare sector has dropped its sales by -20.00% annually for the last half of the decade. When this article was written, the company’s average yearly earnings per share was at 27.26%. With a float of $51.92 million, this company’s outstanding shares have now reached $131.16 million.
In an organization with 214 employees, it is important to assess its efficiency. In terms of profitability, gross margin is 98.55%, operating margin of -496.77%, and the pretax margin is -480.61%.
Prime Medicine Inc (PRME) Insider and Institutional Ownership
Also, it is sometimes useful to examine the sentiment of large-scale investors toward Prime Medicine Inc stocks. The insider ownership of Prime Medicine Inc is 60.42%, while institutional ownership is 31.20%.
Prime Medicine Inc (PRME) Latest Financial update
According to the Wall Street analysts, stocks earnings will be around 27.26% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 12.59% during the next five years compared to -124.13% drop over the previous five years of trading.
Prime Medicine Inc (NASDAQ: PRME) Trading Performance Indicators
You can see what Prime Medicine Inc (PRME) is doing with its current performance indicators. In the most recent quarter, the stock posted a quick ratio of 5.58. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 77.46.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -1.70, a number that is poised to hit -0.31 in the next quarter and is forecasted to reach -1.14 in one year’s time.
Technical Analysis of Prime Medicine Inc (PRME)
Let’s dig in a bit further. During the last 5-days, its volume was 1.55 million. That was better than the volume of 1.1 million it reported in year-ago period. As of the previous 9 days, the stock’s Stochastic %D was 9.73%. Additionally, its Average True Range was 0.22.
During the past 100 days, Prime Medicine Inc’s (PRME) raw stochastic average was set at 3.59%, which indicates a significant decrease from 10.69% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 98.33% in the past 14 days, which was higher than the 85.28% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $2.6434, while its 200-day Moving Average is $3.9625. However, in the short run, Prime Medicine Inc’s stock first resistance to watch stands at $1.8200. Second resistance stands at $1.8800. The third major resistance level sits at $1.9650. If the price goes on to break the first support level at $1.6750, it is likely to go to the next support level at $1.5900. The third support level lies at $1.5300 if the price breaches the second support level.
Prime Medicine Inc (NASDAQ: PRME) Key Stats
There are 131,161K outstanding shares of the company, which has a market capitalization of 230.84 million. As of now, sales total 2,980 K while income totals -195,880 K. Its latest quarter income was 2,180 K while its last quarter net income were -42,280 K.
